Publications by authors named "Shuchi Pandya"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,509

Total Likes

603

Extended Reach

8,000,823

Social Features

213
V
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.
Timothy F Cloughesy, Martin J van den Bent, Mehdi Touat, Deborah T Blumenthal, Katherine B Peters, Shuchi S Pandya

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.
Bin Fan, Ghassan K Abou-Alfa, Andrew X Zhu, Shuchi S Pandya, Hongxia Jia

Cancer Chemother Pharmacol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Ingo K Mellinghoff, Min Lu, Patrick Y Wen, Jennie W Taylor, Elizabeth A Maher, Shuchi S Pandya

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
Courtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, Richard M Stone, Jessica K Altman, Shuchi S Pandya

Am J Hematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Ingo K Mellinghoff, Min Lu, Patrick Y Wen, Jennie W Taylor, Elizabeth A Maher, Shuchi S Pandya

Nat Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib.
Benjamin M Ellingson, Grace Hyun J Kim, Matt Brown, Jihey Lee, Noriko Salamon, Shuchi S Pandya

Neuro Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivosidenib and Azacitidine in -Mutated Acute Myeloid Leukemia.
Pau Montesinos, Christian Recher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Shuchi S Pandya

N Engl J Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Andrew X Zhu, Teresa Macarulla, Milind M Javle, R Kate Kelley, Sam J Lubner, Shuchi S Pandya

JAMA Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Ingo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, Howard A Burris, Elizabeth A Maher, Shuchi S Pandya

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant- cholangiocarcinoma.
Elia Aguado-Fraile, Ania Tassinari, Yuko Ishii, Carlie Sigel, Maeve A Lowery, Shuchi S Pandya

Future Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivosidenib in Isocitrate Dehydrogenase 1Mutated Advanced Glioma.
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, Elizabeth Maher, Macarena I De La Fuente, Shuchi S Pandya

J Clin Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply.
Ghassan K Abou-Alfa, Shuchi S Pandya, Andrew X Zhu

Lancet Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Shuchi S Pandya

Lancet Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
William D Tap, Victor M Villalobos, Gregory M Cote, Howard Burris, Filip Janku, Shuchi S Pandya

J Clin Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Bin Fan, Ingo K Mellinghoff, Patrick Y Wen, Maeve A Lowery, Lipika Goyal, Shuchi S Pandya

Invest New Drugs· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Maeve A Lowery, Howard A Burris, Filip Janku, Rachna T Shroff, James M Cleary, Shuchi S Pandya

Lancet Gastroenterol Hepatol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Rebecca A Miksad, Mohamedtaki A Tejani, Stephen Williamson, Martin E Gutierrez, Shuchi S Pandya

Oncologist· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two cases of disseminated infection following live organism anti-cancer vaccine administration in cancer patients.
James D Denham, Dae Hyun Lee, Manuel Castro, Shuchi Pandya, Sadaf Aslam

Int J Infect Dis· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab.
Wonhee So, Shuchi Pandya, Rod Quilitz, Bijal Shah, John N Greene

Mediterr J Hematol Infect Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Martin H Voss, Rupal S Bhatt, Elizabeth R Plimack, Brian I Rini, Robert S Alter, Shuchi S Pandya

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Suzanne F Jones, Lillian L Siu, Johanna C Bendell, James M Cleary, Albiruni R A Razak, Shuchi S Pandya

Invest New Drugs· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Geoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, Eunice L Kwak, Jose Baselga, Shuchi S Pandya

Clin Cancer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Leena Gandhi, Rastislav Bahleda, Sara M Tolaney, Eunice L Kwak, James M Cleary, Shuchi S Pandya

J Clin Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Daniel B Costa, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen

J Clin Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis